Opinion

Video

Addressing Potential Barriers to the Adoption of Afami-Cel Therapy

A panelist discusses how key barriers to broad afamitresgene autoleucel (afami-cel) adoption include manufacturing turnaround times, the need for specialized cell therapy centers, testing requirements, and coordination of lymphodepletion timing, though these challenges are being actively addressed through improved processes and infrastructure development.

Related Videos
5 experts are featured in this series
5 experts are featured in this series
2 expert is featured in this series.